Higher baseline WMH volume and higher GFAP were associated with a greater likelihood of diagnostic progression. 5 key findings →
Participants: 24 Evidence: low
Full summary, score breakdown and related studies → Original source
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
54/100
BackgroundCognitive impairment significantly impacts the quality of life in patients with neurodegenerative disorders, including Huntington's disease (HD), Parkinson's disease (PD), and Alzheimer's disease (AD).ObjectiveThis study aims to assess the utility of MemTrax, a contemporary digital continuous recognition task platform originally developed for AD, as an effective tool for revealing cognitive and clinical motor impairments in HD and PD populations as aligned with respective disease staging. 2 key findings →
Participants: 135 Evidence: low
Full summary, score breakdown and related studies → Original source
Survivors of childhood cancer are prone to neurocognitive impairment and premature aging, raising concerns about early onset dementia. 3 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Differential FTP-PET signal patterns showed significant negative associations with domain-specific annual rates of decline. 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
Twenty-six percent of participants were PET positive. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Intergrader agreements for overall 3 × 3 mm image quality and quantitative assessment of VD and FAZ ranged between 71% and 87% (52 images). 5 key findings →
Participants: 27 Evidence: low
Full summary, score breakdown and related studies → Original source
Subjective cognitive decline (SCD) serves as an initial symptom of preclinical Alzheimer's disease (AD). 4 key findings →
Participants: 57 Evidence: moderate
Full summary, score breakdown and related studies → Original source
We identified GLP-1 receptor agonist initiation compared to DPP-4 inhibitors initiation was associated with a reduced risk of AD (hazard ratio [HR] ≤ 0.69 and P value < 0.001) and SGLT-2 inhibitor initiation compared to DPP-4 inhibitor initiation was associated with a reduced risk of AD (HR ≤ 0.67 and P value < 0.001). 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Overall, 74 studies containing 92 cases were found of MDs related to ACHEIs. 5 key findings →
Participants: 33 Evidence: low
Full summary, score breakdown and related studies → Original source
Among the air toxics, higher 1,3-butadiene levels we estimated a hazard ratio of 1.12 (95 % CI: 1.00, 1.25) for incident dementia/CIND per IQR increase in 1,3-butadiene exposures. 5 key findings →
Participants: 1,612 Evidence: low
Full summary, score breakdown and related studies → Original source
The etiology of cerebrovascular pathology is heterogeneous. 3 key findings →
Participants: 29 Evidence: low
Full summary, score breakdown and related studies → Original source
54/100
Minoritized individuals had lower scores and/or greater likelihood of impairment on measures of lexical retrieval, processing speed, cognitive flexibility, and working memory but not global cognition, verbal recall, attention, and category fluency. 5 key findings →
Participants: 56 Evidence: low
Full summary, score breakdown and related studies → Original source
In this real-world dataset, we identified effects of multimorbidities on plasma biomarkers, especially kidney function. 2 key findings →
Design: cross-sectional Participants: 617 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
53/100
Amyloid burden is an important prognostic marker in a clinically heterogeneous cohort. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
53/100
Diagnosing Alzheimer's disease (AD) in adults with Down syndrome (DS), a population with a high genetically determined risk of AD, remains challenging. 1 key finding →
Participants: 2,329 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD), the leading cause of dementia, is characterized by the accumulation of amyloid plaques and neurofibrillary tangles in the brain. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
α-Synuclein (αSyn) seed amplification assays (SAAs) accurately detect αSyn pathology in dementia with Lewy bodies (DLB). 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Analysis included a total of 121 145 patients in non-D-SNP plans with an enrollment of 173 662 patient-years (mean [SD] age, 81.8 [7.8] years; 122 565 female [70.6%]; 6078 Asian [3.5%], 34 150 Black [19.7%], 37 580 Hispanic [21.6%], 95 854 White [55.2%]) and 78 166 patients in D-SNP plans with an enrollment of 122 681 patient-years (mean [SD] age, 80.2 [8.0] years; 87 329 female [71.2%]; 10 530 Asian [8.6%], 33 280 Black [27.1%], 43 294 Hispanic [35.3%], 35 577 White [29.0%]). 5 key findings →
Design: cross-sectional Participants: 121 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Overall, 430 093 participants were included. 5 key findings →
Design: cohort study Participants: 93 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Time is an under-recognised social determinant of brain health, and is potentially as important as education or income for dementia risk. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Lifestyle behavioral change is a critical component for secondary prevention of stroke. 1 key finding →
Design: longitudinal study Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
BackgroundWith the changing demographic landscape in most countries worldwide, early identification of cognitive impairment in multicultural populations is increasingly relevant. 2 key findings →
Design: cross-sectional Participants: 187 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The complexity of neurodegenerative disorders necessitates an integrative approach that incorporates morphological, functional, and molecular biomarkers. 3 key findings →
Participants: 279 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
TabCAT tests showed good convergent validity with traditional pen-and-paper tests. 5 key findings →
Design: longitudinal study Participants: 146 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Dementia risk was significantly higher in patients with epilepsy compared with that of controls (IRR: 3.65; 95% CI: 3.14-4.24), especially within the first 2 years post-diagnosis (aHR: 5.42; 95% CI: 4.30-6.83), peaking between 8 and 10 years (aHR: 8.25; 95% CI: 3.15-21.5). 5 key findings →
Design: cohort study Participants: 2,740 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →